Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03660072

Enrollment

Registered

2018-09-06

Start date

2022-01-31

Completion date

2022-10-28

Last updated

2022-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult participants who have a confirmed diagnosis of Multiple Myeloma (MM)

Exclusion criteria

* Participants who use Empliciti for therapeutic indications which are not approved for Empliciti combination therapy in Korea * Patients in whom treatment with Empliciti (as clarified in the Korean label) is contraindicated Other protocol defined inclusion/

Design outcomes

Primary

Measure	Time frame
Incidence of AE's and SAE's	24 Months

Secondary

Measure	Time frame
Overall response of Empliciti treatment with lenalidomide and dexamethasone	24 Months
Incidence of infusion-related reactions associated with Empliciti treatment in combination with lenalidomide and dexamethasone	24 Months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026